Specifically, the combination of avasimibe and imatinib synergistically inhibited BCR-ABL mutation- and nonmutation-dependent imatinib CML cell proliferation by targeting cancer-specific CE accumulation, MAPK and natural BCR-ABL signaling161. Here, ABL1 is linked to cancer.